Full text
Earnings transcript
Read the complete earnings call transcript.
LLY
Eli Lilly and Company
$1115.25
-7.75
(-0.69%)
| Exchange: | NYSE |
| Market Cap: | 1.05T |
| Shares Outstanding: | 1.101B |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Drug Manufacturers – GeneralView industry performance | |||||
| CEO: | David A. Ricks | |||||
| Full Time Employees: | 50000 | |||||
| Address: |
| |||||
| Website: | https://www.lilly.com |
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin’s lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 34,124,100 | 45,042,700 | 65,179,000 |
| Gross Profit | 27,041,900 | 36,624,400 | 54,615,000 |
| EBITDA | 8,567,800 | 15,227,600 | 27,936,500 |
| Operating Income | 10,787,300 | 17,501,700 | 29,696,000 |
| Net Income | 5,240,400 | 10,590,000 | 20,638,300 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 64,006,300 | 78,714,900 | 112,476,000 |
| Total Liabilities | 53,142,600 | 64,443,300 | 85,941,000 |
| Total Stockholders Equity | 10,771,900 | 14,192,100 | 26,535,000 |
| Total Debt | 25,225,300 | 33,644,200 | 42,503,000 |
| Cash and Cash Equivalents | 2,818,600 | 3,268,400 | 7,268,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 4,240,100 | 8,817,900 | 16,813,000 |
| Capital Expenditure | -7,392,100 | -8,403,600 | -7,841,000 |
| Free Cash Flow | -3,152,000 | 414,300 | 8,972,000 |
| Net Income | 5,240,400 | 10,590,000 | 20,640,000 |
| Net Change in Cash | 751,600 | 449,800 | 4,000,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 123,077,058.086 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 141,934,703.810 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 132,394,916.667 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 75,474,370.222 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 88,383,383.325 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 81,852,918.096 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 53,976,718.135 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 64,977,862.268 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 59,412,557.727 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 24,212,553.061 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 27,922,356.941 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 26,045,625.356 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 66.160 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 72.360 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 60.110 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 12 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 3 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates LLY intrinsic value between $279.31 – $950.77 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about LLY valuation
Is Eli Lilly and Company (LLY) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Eli Lilly and Company (LLY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is LLY a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LLY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is LLY’s P/E ratio?
You can see LLY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for LLY?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is LLY a good long-term investment?
Whether LLY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
LLY
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.69
Trading Metrics:
| Open: | 1127.63 | Previous Close: | 1123 | |
| Day Low: | 1113.29 | Day High: | 1131.44 | |
| Year Low: | 712.05 | Year High: | 1292.65 | |
| Price Avg 50: | 1186.18 | Price Avg 200: | 1064.57 | |
| Volume: | 1.83M | Average Volume: | 2.922M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeLLY full analysis
Hey everyone, welcome back. Today we’re diving into one of the most talked-about names in the entire market—Eli Lilly. This company just became the first pharmaceutical firm ever to hit a trillion-dollar market cap. The stock has surged past $1,000 a share, and there’s a lot of buzz around its obesity drugs, its pipeline, and even President Trump loading up on shares. But is Lilly still a buy at these levels, or has the market already priced in all the…
